Contact
Please use this form to send email to PR contact of this press release:
In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing
TO:
Please use this form to send email to PR contact of this press release:
In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing
TO: